

Date: 12th August, 2024

To,
The Manager,
Department of Corporate Services,
BSE Limited
1st Floor, Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai - 400 001
Scrip Code: 506235

To,
The Manager,
Listing Department,
National Stock Exchange of India Limited
"Exchange Plaza"
Bandra Kurla Complex, Bandra (E),
Mumbai – 400 051
NSE Symbol: ALEMBICLTD

Dear Sir,

Sub: Outcome of Board Meeting

With reference to the captioned subject, the exchange is hereby informed that the Board of Directors of Alembic Limited at its meeting held today has *inter alia* approved the Unaudited Financial Results of the Company for the quarter ended 30th June, 2024:

We enclose herewith the following:

- Consolidated Unaudited Financial Results for the quarter ended 30th June, 2024.
- Standalone Unaudited Financial Results for the quarter ended 30th June, 2024.
- Limited Review Report by Statutory Auditors on the Consolidated and Standalone Unaudited Financial Results.


The time of commencement of the Board Meeting was 3:00 p.m. and the time of conclusion was 3:40 p.m.

We request you to kindly take the same on record.

Thanking you,

Yours faithfully,


For Alembic Limited


Keval Thakkar
Company Secretary



Encl.: A/a

ALEMBIC LIMITED



ALEMBIC LIMITED

CIN:L26100GJ1907PLC000033

Regd.Office: Alembic Road, Vadodara 390 003

Ph:0265 6637000

www.alembiclimited.com Email:alembic.investors@alembic.co.in

Statement of Consolidated Unaudited Financial Results for the Quarter ended 30th June, 2024

Sr. No	Particulars	Quarter Ended			Rs. in Lakhs
		30.06.2024 (Unaudited)	31.03.2024 (Audited)	30.06.2023 (Unaudited)	31.03.2024 (Audited)
1	Revenue from Operations	5,078	4,904	3,684	15,749
2	Other Income	196	204	263	5,477
3	Total Income	5,274	5,108	3,947	21,226
4	Expenses				
	Cost of Materials Consumed	286	323	134	862
	Cost of Construction	1,191	974	923	3,981
	Changes in Inventories of Finished Goods and WIP	131	(102)	247	53
	Employee Benefit Expenses	773	555	627	2,303
	Finance Costs	49	48	13	111
	Depreciation and amortisation expense	250	148	183	784
	Other Expenses	657	739	665	2,864
	Total Expenses	3,337	2,685	2,793	10,957
5	Profit Before Tax (3-4)	1,937	2,423	1,155	10,269
6	Tax Expenses				
	Current Tax	234	424	113	1,002
	Deferred Tax	(38)	73	46	482
	Short / (Excess) Provision of earlier years	-	(203)	-	(502)
7	Net Profit after tax for the Period	1,742	2,129	996	9,287
8	Share of Associate's Profit/(Loss)	3,840	5,086	3,442	17,575
9	Net Profit/(Loss) after tax and Share of Associate's Profit/(Loss)	5,582	7,215	4,438	26,862
10	Other Comprehensive Income				
	A (i) Items that will not be reclassified to Profit or (Loss)	4,348	(6,065)	4,004	(6,855)
	(ii) Income tax relating to items that will not be reclassified to Profit or (Loss)	(490)	666	(453)	775
	B (i) Items that will be reclassified to Profit or (Loss)	(3)	34	(24)	108
11	Total Comprehensive Income/(Loss) for the Period	9,436	1,849	7,965	20,890
12	Paid up Equity Share Capital (Face Value of Rs 2/- per share)	5,135.64	5,135.64	5,135.64	5,135.64
13	Other Equity (excluding Revaluation Reserve)				1,85,911
14	Earnings per equity share (FV Rs. 2/- per share) Basic & Diluted (In Rs.)	2.17	2.81	1.73	10.46



Alembic Limited
Segment wise Consolidated Revenue and Results

Rs. in Lakhs

Sr. No	Particulars	Quarter Ended			Year Ended
		30.06.2024 (Unaudited)	31.03.2024 (Audited)	30.06.2023 (Unaudited)	31.03.2024 (Audited)
1	Segment Revenue				
	Revenue from Operations				
	a. Active Pharmaceutical Ingredients Business	1,072	797	944	3,174
	b. Real Estate Business	4,006	4,107	2,740	12,574
	Total Income from Operations (Net)	5,078	4,904	3,684	15,749
2	Segment Results (Profit (+)/ Loss (-) before Taxes and interest from each segment)				
	a. Active Pharmaceutical Ingredients Business	50	98	45	336
	b. Real Estate Business	1,924	2,349	976	5,126
	Total	1,974	2,447	1,022	5,462
	Unallocable Income and Expenditure				
	(i) Interest Expense	(49)	(48)	(13)	(111)
	(ii) Dividend Income and Gain/(Loss) on Fair Value Change of Financial Asset	31	23	124	4,869
	(iii) Other Income / (Expense)	(20)	-	22	49
	Total Profit Before Tax	1,937	2,423	1,155	10,269
3	Segment Assets				
	a. Active Pharmaceutical Ingredients Business	18,752	18,380	18,674	18,380
	b. Real Estate Business	39,663	36,700	30,800	36,700
	c. Unallocated	1,86,495	1,77,798	1,79,722	1,77,798
	Total	2,44,910	2,32,877	2,29,196	2,32,877
4	Segment Liabilities				
	a. Active Pharmaceutical Ingredients Business	3,582	2,941	2,918	2,941
	b. Real Estate Business	8,987	7,682	6,527	7,682
	c. Unallocated	4,349	3,698	3,983	3,698
	Total	16,918	14,321	13,428	14,321

Notes:

- The above results have been reviewed by Statutory Auditors, recommended by Audit Committee and approved by the Board of Directors of the Company.
- The figures for quarter ended 31st March 2024 are the balancing figures between the audited figures in respect of full financial year ended 31st March 2024 and year to date unaudited figures up to the third quarter ended 31st December 2023.
- The previous quarter's / year's figures have been regrouped / rearranged wherever necessary to make it comparable with the current quarter / year.

Place : Vadodara
Date : 12th August, 2024



For Alembic Limited

Chirayu Amin
Chairman



ALEMBIC LIMITED

CIN:L26100GJ1907PLC000033

Regd.Office: Alembic Road, Vadodara 390 003

Ph:0265 6637000

www.alembiclimited.com Email:alembic.investors@alembic.co.in

Statement of Standalone Unaudited Financial Results for the Quarter ended 30th June, 2024

Rs. in Lakhs

Sr. No.	Particulars	Quarter Ended			Year Ended
		30.06.2024 (Unaudited)	31.03.2024 (Audited)	30.06.2023 (Unaudited)	31.03.2024 (Audited)
1	Revenue from Operations	4,908	4,751	3,565	15,225
2	Other Income	189	195	259	5,462
3	Total Income	5,097	4,946	3,824	20,687
4	Expenses				
	Cost of Materials Consumed	286	323	134	862
	Cost of Construction	1,191	974	923	3,981
	Changes in Inventories of Finished Goods and WIP	131	(102)	247	53
	Employee Benefit Expenses	773	555	627	2,303
	Finance Costs	34	33	5	69
	Depreciation and amortisation expense	241	138	174	746
	Other Expenses	582	663	623	2,402
	Total Expenses	3,238	2,585	2,733	10,415
5	Profit Before Tax (3-4)	1,859	2,361	1,091	10,272
6	Tax Expenses				
	Current Tax	213	422	96	1,000
	Deferred Tax	(37)	73	47	484
	Short / (Excess) Provision of earlier years	-	(202)	-	(501)
7	Net Profit after tax for the Period	1,684	2,068	948	9,289
8	Other Comprehensive Income				
	(i) Items that will not be reclassified to Profit or (Loss)	4,459	(5,686)	4,007	(6,409)
	(ii) Income tax relating to items that will not be reclassified to Profit or (Loss)	(510)	649	(453)	747
9	Total Comprehensive Income/(Loss) for the Period	5,633	(2,969)	4,502	3,627
10	Paid up Equity Share Capital (Face Value of Rs 2/- per share)	5,135.64	5,135.64	5,135.64	5,135.64
11	Other Equity (excluding Revaluation Reserve)				48,231
12	Earnings per equity share (FV Rs. 2/- per share) Basic & Diluted (In Rs.)	0.66	0.81	0.37	3.62



Alembic Limited
Segment wise Standalone Revenue and Results

Rs. in Lakhs

Sr. No.	Particulars	Quarter Ended			Year Ended
		30.06.2024 (Unaudited)	31.03.2024 (Audited)	30.06.2023 (Unaudited)	31.03.2024 (Audited)
1	Segment Revenue				
	Revenue from Operations				
	a. Active Pharmaceutical Ingredients Business	1,072	797	944	3,174
	b. Real Estate Business	3,835	3,954	2,621	12,051
	Total Income from Operations (Net)	4,908	4,751	3,565	15,225
2	Segment Results (Profit (+)/ Loss (-) before Taxes and interest from each segment)				
	a. Active Pharmaceutical Ingredients Business	50	98	45	336
	b. Real Estate Business	1,831	2,272	905	5,087
	Total	1,881	2,371	950	5,423
	Unallocable Income and Expenditure				
	(i) Interest Expense	(34)	(33)	(5)	(69)
	(ii) Dividend Income and Gain/(Loss) on Fair Value Change of Financial Asset	31	23	124	4,869
	(iii) Other Income / (Expense)	(20)	-	22	49
	Total Profit Before Tax	1,859	2,361	1,091	10,272
3	Segment Assets				
	a. Active Pharmaceutical Ingredients Business	18,752	18,380	18,674	18,380
	b. Real Estate Business	38,784	35,897	30,069	35,897
	c. Unallocated	45,057	40,310	51,555	40,310
	Total	1,02,592	94,587	1,00,298	94,587
4	Segment Liabilities				
	a. Active Pharmaceutical Ingredients Business	3,582	2,941	2,918	2,941
	b. Real Estate Business	8,154	6,941	5,999	6,941
	c. Unallocated	4,347	3,829	3,979	3,829
	Total	16,084	13,711	12,897	13,711

Notes:

- The above results have been reviewed by Statutory Auditors, recommended by Audit Committee and approved by the Board of Directors of the Company.
- The figures for quarter ended 31st March 2024 are the balancing figures between the audited figures in respect of full financial year ended 31st March 2024 and year to date unaudited figures up to the third quarter ended 31st December 2023.
- The previous quarter's / year's figures have been regrouped / rearranged wherever necessary to make it comparable with the current quarter / year.

Place : Vadodara
Date : 12th August, 2024



For Alembic Limited

Chirayu Amin
Chairman

Independent Auditor's Review Report on Unaudited Consolidated Quarterly Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of Alembic Limited


1. We have reviewed the accompanying Statement of unaudited consolidated financial results of Alembic Limited ("the Parent") and its subsidiary (the Parent and its subsidiary together referred to as "the Group") for the quarter ended 30th June, 2024 ("the Statement") attached herewith, being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirement) Regulations, 2015, as amended (the "Listing Regulations").
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34, ("Ind AS 34") "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statements based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the Securities Exchange Board of India under Regulation 33 (8) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, to the extent applicable.

4. Emphasis of Matter

We draw attention to the status of disputed liability related to pending electricity duty matter. During the previous period's, the Company had made aggregate provision towards total principal amount being Rs. 2,052.13 lakhs for the disputed matter(s) filed against State of Gujarat, Collector of Electricity Duty & others. The interest amount thereon is not ascertainable and is disclosed as contingent liability in the Consolidated Financial Statements for the year ended 31st March, 2024. Further, the Company has deposited Rs. 35 Crores with the Hon'ble Supreme Court on 26th May, 2023 and the appeal filed by the Company has been admitted.

Our opinion is not modified in respect of above matter.



The Nirat, 3rd Floor, 18, Winward Business Park, Behind Emerald One Complex, In the lane of Dr. Prasant Buch's Hospital, Jetalpur, Vadodara 390 007. Tel: +91 265 234 3483

Website: www.cnkindia.com

VADODARA | MUMBAI | CHENNAI | AHMEDABAD | GIFT CITY | BENGALURU | DELHI | PUNE | DUBAI | ABU DHABI

5. The statement includes results of the following entities:
- Alembic City Limited (Subsidiary)
 - Alembic Pharmaceuticals Limited (Associate)
6. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration referred to in paragraph 7 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.
7. We did not review the financial result of a subsidiary included in the unaudited consolidated financial results, whose financial results reflect total revenue of Rs. 888.62 lakhs, total net loss after tax of Rs.52.30 lakhs and total comprehensive loss of Rs. 52.33 lakhs for the quarter ended 30th June, 2024. The unaudited consolidated financial results also include the Group's share of net profit after tax of Rs. 3,839.68 lakhs and total comprehensive income of Rs. 3,744.36 lakhs for the quarter ended 30th June, 2024, as considered in the statement, in respect of an associate. These financial results have been reviewed by other auditors whose reports have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of a subsidiary and associate, is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above.

Our conclusion on the unaudited consolidated quarterly financial results is not modified with respect of the above matter.

For C N K & Associates LLP
Chartered Accountants
Firm Registration No. 101961W/W-100036

Rachit

Rachit Sheth
Partner
Membership No.158289
Place: Vadodara
Date: 12th August, 2024
UDIN: 24158289BKAQLU7749



Independent Auditor's Review Report on Unaudited Standalone Quarterly Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of Alembic Limited

1. We have reviewed the accompanying Statement of Unaudited Standalone Financial results of Alembic Limited ("the Company") for the quarter ended 30th June, 2024 ("the Statement") attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirement) Regulations, 2015, as amended (the "Listing Regulations").
2. This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34, ("Ind AS 34") "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statements based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



The Nirat, 3rd Floor, 18, Winward Business Park, Behind Emerald One Complex, In the lane of Dr. Prasant Buch's Hospital, Jetalpur, Vadodara 390 007. Tel: +91 265 234 3483

Website: www.cnkindia.com

VADODARA | MUMBAI | CHENNAI | AHMEDABAD | GIFT CITY | BENGALURU | DELHI | PUNE | DUBAI | ABU DHABI

4. Emphasis of Matter

We draw attention to the status of disputed liability related to pending electricity duty matter. During the previous periods, the Company had made aggregate provision towards total principal amount being Rs. 2,052.13 lakhs for the disputed matter(s) filed against State of Gujarat, Collector of Electricity Duty & others. The interest amount thereon is not ascertainable and is disclosed as contingent liability in the Standalone Financial Statements for the year ended 31st March, 2024. Further, the Company has deposited Rs. 35 Crores with the Hon'ble Supreme Court on 26th May, 2023 and the appeal filed by the Company has been admitted.

Our opinion is not modified in respect of above matter.

5. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement of Unaudited standalone financial results prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which, it is to be disclosed, or that it contains any material misstatement.

For C N K & Associates LLP

Chartered Accountants

Firm Registration No. 101961W/W-100036

Rachit Sheth

Rachit Sheth

Partner

Membership No.158289

Place: Vadodara

Date: 12th August, 2024

UDIN: 24158289BKAQLT6896

